NRx Pharmaceuticals appoints Michael Abrams as permanent CFO, base salary $325,000

NRX Pharmaceuticals, Inc.

Michael Abrams appointed CFO effective Nov 18, 2024, succeeding interim CFO Richard Narido.
Base salary $325,000; initially 50% until Qualified Financing or Feb 1, 2025.
Granted 50,000 stock options under 2021 Omnibus Incentive Plan, vesting over three years.
Abrams previously CFO at Arch Therapeutics, RiseIT Solutions, and FitLife Brands.
Employment agreement includes non-compete, non-solicitation, and severance provisions.

item 1.01 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Richard Narido

Interim Chief Financial Officer

NRXP · NRX Pharmaceuticals, Inc.

Effective: 2024-11-18
Successor: Michael Abrams
Filed: November 20, 2024, 6:59 PM ET

Mr. Abrams succeeds Interim Chief Financial Officer Richard Narido, who will continue to support the Company’s financial function and other projects.

Appointed

Michael Abrams

Chief Financial Officer

NRXP · NRX Pharmaceuticals, Inc.

Effective: 2024-11-18
Successor: Richard Narido
Filed: November 20, 2024, 6:59 PM ET

On November 18, 2024, NRx Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing the appointment of Michael Abrams as the Chief Financial Officer of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.85

Richard Narido changed role as Interim Chief Financial Officer at NRX Pharmaceuticals, Inc..

Action: succeeded
Role: Interim Chief Financial Officer

Exact text from the filing

Mr. Abrams succeeds Interim Chief Financial Officer Richard Narido, who will continue to support the Company’s financial function and other projects.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Abrams was appointed as Chief Financial Officer at NRX Pharmaceuticals, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On November 18, 2024, NRx Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing the appointment of Michael Abrams as the Chief Financial Officer of the Company.

View on SEC.gov

NRX Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-24-035806

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.